SEHK:1952Biotechs
Everest Medicines (SEHK:1952) Is Up 15.7% After Revenue Surges And Loss Narrows In 2025 Results - Has The Bull Case Changed?
Everest Medicines Limited recently reported full-year 2025 results, with sales of CNY 1,706.68 million versus CNY 706.68 million a year earlier and a net loss of CNY 297.77 million compared with CNY 1,041.38 million, alongside presentations at the American College of Cardiology 75th Annual Scientific Session in New Orleans in March 2026.
The sharp increase in revenue and much smaller loss per share point to materially improved operating efficiency that could reshape how investors view the...